Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

2,395 questions in 172 reviews · Gut

current versions

No studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Continuous veno‐venous hemofiltration (CVVH) vs no CVVH Total hospital cost · adults with severe acute pancreatitis Continuous veno‐venous hemofiltration for severe acute pancreatitis (2019) · Cochrane	no estimate extracted	1 study · 125 participants	Very low
Continuous veno‐venous hemofiltration (CVVH) vs no CVVH Quality of life · adults with severe acute pancreatitis Continuous veno‐venous hemofiltration for severe acute pancreatitis (2019) · Cochrane	no estimate extracted	NR	No studies
High‐volume continuous veno‐venous hemofiltration (CVVH) vs standard CVVH All‐cause mortality · adults with severe acute pancreatitis Continuous veno‐venous hemofiltration for severe acute pancreatitis (2019) · Cochrane	RR 0.6 [0.17, 2.07]	1 study · 30 participants	Low
High‐volume continuous veno‐venous hemofiltration (CVVH) vs standard CVVH Adverse events · adults with severe acute pancreatitis Continuous veno‐venous hemofiltration for severe acute pancreatitis (2019) · Cochrane	RR 1 [0.16, 6.2]	1 study · 30 participants	Very low
High‐volume continuous veno‐venous hemofiltration (CVVH) vs standard CVVH Length of ICU stay · adults with severe acute pancreatitis Continuous veno‐venous hemofiltration for severe acute pancreatitis (2019) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Placebo Comparator · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	no estimate extracted	NR	Low
Intervention NR Sulfasalazine (2 RCTs; 143 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.89 [0.55, 1.3]	2 studies · 143 participants	Very low
Intervention NR Antibiotics (2 RCTs; 57 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.98 [0.5, 1.71]	2 studies · 57 participants	Very low
Intervention NR Probiotics (2 RCTs; 105 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 1.11 [0.62, 1.88]	2 studies · 105 participants	Very low
Intervention NR Sulfasalazine + prednisolone (1 RCT; 57 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 1.37 [0.5, 3.07]	1 study · 57 participants	Very low
Intervention NR Placebo (16 RCTs; 935 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	no estimate extracted	16 studies · 935 participants	Ungraded
Intervention NR Adalimumab (3 RCTs; 37 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.1 [0.01, 0.32]	3 studies · 37 participants	Low
Intervention NR Infliximab (2 RCTs; 21 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.24 [0.01, 1.2]	2 studies · 21 participants	Low
Intervention NR Antibiotics (2 RCTs; 57 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.8 [0.33, 1.65]	2 studies · 57 participants	Very low
Intervention NR Purine analogues (4 RCTs; 164 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.85 [0.33, 1.61]	4 studies · 164 participants	Very low
Intervention NR Probiotics (3 RCTs; 108 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 1.2 [0.62, 2.19]	3 studies · 108 participants	Very low
Intervention NR Rank 8 (6 to 10) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	no estimate extracted	NR	Low
Intervention NR 5‐ASA (3 RCTs; 237 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 1.22 [0.61, 2.18]	3 studies · 5 participants	Very low
Intervention NR Placebo (8 RCTs; 507 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	no estimate extracted	8 studies · 507 participants	Ungraded
Intervention NR Sulfasalazine (1 RCT; 32 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 1.96	1 study · 32 participants	Very low
Intervention NR Infliximab (1 RCT; 11 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 6.37	1 study · 11 participants	Very low
Intervention NR 5‐ASA (8 RCTs; 371 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 1.19 [0.39, 3.14]	5 studies · 8 participants	Very low
Intervention NR Budesonide (2 RCTs; 106 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 1.64 [0.17, 6.19]	2 studies · 106 participants	Very low
Intervention NR Probiotic (1 RCT; 58 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 2.44 [0.13, 9]	1 study · 58 participants	Very low
Intervention NR Adalimumab (1 RCT; 16 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 11.74 [0.12, 55.06]	1 study · 16 participants	Very low
Intervention NR Purine analogues (7 RCTs; 315 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 2.51 [0.79, 7.35]	7 studies · 315 participants	Very low
Intervention NR Antibiotics (1 RCT; 16 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 53.92 [0.43, 259.8]	1 study · 16 participants	Very low
Intervention NR Rank 5 (3 to 7) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	no estimate extracted	NR	Low
Intervention NR Placebo (10 RCTs; 531 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	no estimate extracted	10 studies · 531 participants	Ungraded
Intervention NR Rank 4 (2 to 7) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	no estimate extracted	NR	Very low
Intervention NR Adalimumab (2 RCTs; 26 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.11 [0.02, 0.33]	2 studies · 26 participants	Low
Intervention NR Infliximab (2 RCTs; 21 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.36 [0.02, 1.74]	2 studies · 21 participants	Very low
Intervention NR Budesonide (1 RCT; 43 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.66 [0.27, 1.34]	1 study · 43 participants	Low
Intervention NR 5‐ASA (9 RCTs; 542 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.69 [0.53, 0.87]	5 studies · 9 participants	Moderate
Intervention NR Purine analogues (6 RCTs; 316 participants) · surgically induced remission in Crohn's disease Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis (2019) · Cochrane	HR 0.75 [0.55, 1]	6 studies · 316 participants	Low
Elemental vs non‐elemental enteral feeds Remission rate ‐ Intention to treat · induction of remission in Crohn's disease Enteral nutritional therapy for induction of remission in Crohn's disease (2018) · Cochrane	RR 1.02 [0.88, 1.18]	11 studies · 378 participants	Very low
Elemental vs non‐elemental enteral feeds Adverse events · induction of remission in Crohn's disease Enteral nutritional therapy for induction of remission in Crohn's disease (2018) · Cochrane	RR 1.01 [0.62, 1.65]	9 studies · 323 participants	Very low
Elemental vs non‐elemental enteral feeds Withdrawal due to adverse events · induction of remission in Crohn's disease Enteral nutritional therapy for induction of remission in Crohn's disease (2018) · Cochrane	RR 1.37 [0.83, 2.25]	7 studies · 272 participants	Very low
Enteral nutrition vs corticosteroids Remission rate ‐ ITT · induction of remission in Crohn's disease Enteral nutritional therapy for induction of remission in Crohn's disease (2018) · Cochrane	RR 0.77 [0.58, 1.03]	8 studies · 409 participants	Very low
Enteral nutrition vs corticosteroids Remission rate ‐ ITT adult studies · induction of remission in Crohn's disease Enteral nutritional therapy for induction of remission in Crohn's disease (2018) · Cochrane	RR 0.65 [0.52, 0.82]	6 studies · 352 participants	Very low
Enteral nutrition vs corticosteroids Remission rate ‐ ITT pediatric studies · induction of remission in Crohn's disease Enteral nutritional therapy for induction of remission in Crohn's disease (2018) · Cochrane	RR 1.35 [0.92, 1.97]	2 studies · 57 participants	Very low
Enteral nutrition vs corticosteroids Remission rate ‐ per‐protocol ‐ pediatric studies · induction of remission in Crohn's disease Enteral nutritional therapy for induction of remission in Crohn's disease (2018) · Cochrane	RR 1.43 [1.03, 1.97]	2 studies · 55 participants	Very low
Enteral nutrition vs corticosteroids Adverse events · induction of remission in Crohn's disease Enteral nutritional therapy for induction of remission in Crohn's disease (2018) · Cochrane	RR 1.39 [0.62, 3.11]	7 studies · 389 participants	Very low
Enteral nutrition vs corticosteroids Withdrawal due to adverse events · induction of remission in Crohn's disease Enteral nutritional therapy for induction of remission in Crohn's disease (2018) · Cochrane	RR 2.95 [1.02, 8.48]	3 studies · 169 participants	Very low
Elemental formula supplements vs polymeric formula supplements Relapse · Participants with Crohn's disease in remission Enteral nutrition for maintenance of remission in Crohn's disease (2018) · Cochrane	RR 1.01 [0.56, 1.84]	1 study · 33 participants	Very low
Elemental formula supplements vs no supplementation Change in height · Participants with Crohn's disease in remission Enteral nutrition for maintenance of remission in Crohn's disease (2018) · Cochrane	no estimate extracted	NR	No studies
Elemental formula supplements vs no supplementation Change in quality of life · Participants with Crohn's disease in remission Enteral nutrition for maintenance of remission in Crohn's disease (2018) · Cochrane	no estimate extracted	NR	No studies
Elemental formula supplements vs no supplementation Adverse events · Participants with Crohn's disease in remission Enteral nutrition for maintenance of remission in Crohn's disease (2018) · Cochrane	no estimate extracted	1 study · 51 participants	Ungraded
Elemental formula supplements vs no supplementation Serious adverse events · Participants with Crohn's disease in remission Enteral nutrition for maintenance of remission in Crohn's disease (2018) · Cochrane	no estimate extracted	1 study · 51 participants	Ungraded
Elemental formula supplements vs no supplementation Withdrawal due to adverse events · Participants with Crohn's disease in remission Enteral nutrition for maintenance of remission in Crohn's disease (2018) · Cochrane	no estimate extracted	1 study · 51 participants	Ungraded